Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Pharmaceuticals Holding Co. is conducting a clinical study titled ‘A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of B001 in Subjects With Aquaporin-4 Antibody (AQP4-IgG) Positive Neuromyelitis Optic Spectrum Disorder (NMOSD).’ The study aims to assess the safety and efficacy of B001, a promising treatment for NMOSD, a rare autoimmune disorder. This research is significant as it could lead to a new therapeutic option for patients with limited treatment choices.
The intervention being tested is B001 injection, an experimental drug administered intravenously. It is designed to target and treat NMOSD by addressing the underlying autoimmune response associated with the disease.
The study follows an interventional design with randomized allocation and a parallel intervention model. It employs double masking, meaning both participants and investigators are unaware of who receives the treatment versus the placebo. The primary purpose of the study is treatment-focused.
Key dates for the study include its start on November 21, 2021, and the last update on August 15, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
This update could positively impact Shanghai Pharmaceuticals’ stock performance by boosting investor confidence in the company’s innovative research efforts. The study’s progress may also influence the competitive landscape in the pharmaceutical industry, particularly in the niche market of NMOSD treatments.
The study is ongoing, and further details are available on the ClinicalTrials portal.